New therapeutic landscape of NNRTIs for treatment of HIV: a look at recent data

Bibliography

• DHHS. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. Office of AIDS Research Advisory Council; 2011. p. 1-174
   Google Scholar
• Lennox JL, DeJesus E, Lazzarin A, Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009;374(9692):796-806
   PubMed Web of Science ®Google Scholar
• Mbuagbaw LC, Irlam JH, Spaulding A, Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naive individuals. Cochrane Database Syst Rev (Online) 2010(12):CD004246
   Google Scholar
• Miller CD, Crain J, Tran B, Patel N. Rilpivirine: a new addition to the anti-HIV-1 armamentarium. Drugs Today (Barc) 2011;47(1):5-15
   PubMed Web of Science ®Google Scholar
• Towner WJ, Cassetti I, Domingo P, Etravirine: clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance. Antivir Ther 2010;15(6):803-16
   PubMed Web of Science ®Google Scholar
• Das K, Clark AD Jr, Lewi PJ, Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 2004;47(10):2550-60
   PubMed Web of Science ®Google Scholar
• Basavapathruni A, Vingerhoets J, de Bethune MP, Modulation of human immunodeficiency virus type 1 synergistic inhibition by reverse transcriptase mutations. Biochemistry 2006;45(23):7334-40
   PubMed Web of Science ®Google Scholar
• de Bethune MP. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989 – 2009). Antivir Res 2010;85(1):75-90
   PubMed Web of Science ®Google Scholar
• Squibb BM. Sustiva Prescribing Information. In; 2011
   Google Scholar
• Squibb BM. Atripla Prescibing Information. In; 2010
   Google Scholar
• BIPI. Viramune XR prescribing information. Full prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc; Available from: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Viramune+XR/ViramuneXR.pdf. 2011
   Google Scholar
• Boehringer Ingelheim Pharmaceuticals I. Viramune prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc; Available from: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Viramune/Viramune.pdf. 2011
   Google Scholar
• Tibotec. Edurant (rilpivirine) Tablets Full Prescribing Informantion. In; 2011
   Google Scholar
• Gilead Sciences I. Complera Prescribing Information. 2011
   Google Scholar
• Tibotec. Intelence (etravirine) Tablets Full Prescribing Information. In; 2010
   Google Scholar
• Manosuthi W, Sungkanuparph S, Tantanathip P, A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clin Infect Dis 2009;48(12):1752-9
   PubMed Web of Science ®Google Scholar
• Weiner M, Benator D, Peloquin CA, Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis. Clin Infect Dis 2005;41(9):1343-9
   PubMed Web of Science ®Google Scholar
• van den Berg-Wolf M, Hullsiek KH, Peng G, Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons. HIV Clin Trials 2008;9(5):324-36
   PubMed Web of Science ®Google Scholar
• Riddler SA, Haubrich R, DiRienzo AG, Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008;358(20):2095-106
   PubMed Web of Science ®Google Scholar
• Labarga P, Medrano J, Seclen E, Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients. AIDS (London, England) 2010;24(5):777-9
   PubMed Web of Science ®Google Scholar
• Collaboration H-C. The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. AIDS (London, England) 2012;26(13):1691-705
   PubMed Web of Science ®Google Scholar
• Soriano V, Arasteh K, Migrone H, Nevirapine versus Atazanavir/ritonavir, each combined with Tenofovir/Emtricitabine, in antiretroviral-naive HIV-1 patients: week 48 ArTEN results. Antivir Ther 2011;16(3):339-48
   PubMed Web of Science ®Google Scholar
• DeJesus E, Mills A, Bhatti L, Conner C. A. Randomized Comparison of Safety and Efficacy of Nevirapine vs Atazanavir/Ritonavir Combined with Tenofovir/Emtricitabine in Treatment-Naive Patients. Accepted
   Google Scholar
• Gathe J, Knecht G, Orrell C, 48 Week (Wk) Efficacy, Pharmacokinetics (PK) and Safety of Once a Day (QD) 400 mg Nevirapine (NVP) Extended Release Formulation (XR) for Treatment of Antiretroviral (ARV) Naive HIV-1 Infected Patients (Pts) [VERxVE]. ICAAC; Boston, MA; 2010
   Google Scholar
• Arasteh K, Ward D, Plettenberg A, 24 Wk Efficacy and Safety of Transitioning Virologically Stable HIV-1 Patients from IR Nevirapine 200 mg BID to Nevirapine XR 400 mg QD (TRANxITION). ICAAC; Boston, MA; 2010
   Google Scholar
• Molina JM, Cahn P, Grinsztejn B, Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011;378(9787):238-46
   PubMed Web of Science ®Google Scholar
• Cohen CJ, Andrade-Villanueva J, Clotet B, Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011;378(9787):229-37
   PubMed Web of Science ®Google Scholar
• Cohen C, Molina J, Cahn P, Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive, HIV-1-infected patients: Pooled results from the phase 3 double-blind, randomized ECHO and THRIVE trials. J Acquir Immune Defic Syndr (1999) 2012;60(1):33-42
   PubMed Web of Science ®Google Scholar
• Cohen C, Molina J, Cahn P, Pooled Week 48 efficacy and safety results from ECHO and THRIVE, two double-blind, randomised, Phase III trials comparing TMC278 versus efavirenz in treatment-naive, HIV-1-infected patients. XVIIIth International AIDS Conference; Vienna, Austria; 2010
   Google Scholar
• Tambuyzer L, Vingerhoets J, Azijn H, Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies. AIDS Res Hum Retroviruses 2010;26(11):1197-205
   PubMed Web of Science ®Google Scholar
• Katlama C, Clotet B, Mills A, Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir Ther 2010;15(7):1045-52
   PubMed Web of Science ®Google Scholar
• Gazzard B, Duvivier C, Zagler C, Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results. AIDS 2011;25(18):2249-58
   PubMed Web of Science ®Google Scholar
• Conway B, Wainberg MA, Hall D, Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine. AIDS (London, England) 2001;15(10):1269-74
   PubMed Web of Science ®Google Scholar
• Harrigan PR, Mo T, Wynhoven B, Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2005;19(6):549-54
   PubMed Web of Science ®Google Scholar
• Tambuyzer L, Azijn H, Rimsky LT, Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors. Antivir Ther 2009;14(1):103-9
   PubMed Web of Science ®Google Scholar
• Vingerhoets J, Tambuyzer L, Azijn H, Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS 2010;24(4):503-14
   PubMed Web of Science ®Google Scholar
• Vingerhoets J, Buelens A, Peeters M. Impact of baseline NNRTI mutations on the virological response to TMC125 in the phase III clinical trials DUET-1 and DUET-2. XVI International HIV Drug Resistance Workshop; Barbados; 2007
   Google Scholar
• Tambuyzer L, Nijs S, Daems B, Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine. J Acquir Immune Defic Syndr 2011;58(1):18-22
   PubMed Web of Science ®Google Scholar
• Van der Borght K, Van Craenenbroeck E, Lecocq P, Cross-validated stepwise regression for identification of novel non-nucleoside reverse transcriptase inhibitor resistance associated mutations. BMC Bioinformatics 2011;12:386
   PubMed Web of Science ®Google Scholar
• Etravirine. 2012. Available from: http://aidsinfo.nih.gov/drugs/398/etravirine/professional [Accessed 16 February 2012]
   Google Scholar
• Walmsley S, Antela A, Clumeck N, Dolutegravir (DTG; S/GSK1349572) + Abacavir/Lamivudine Once Daily Statistically Superior to Tenofovir/Emtricitabine/Efavirenz: 48-Week Results - SINGLE (ING114467). 52nd ICAAC Interscience Conference on Antimicrobial Agents and Chemother; San Francisco; 2012
   Google Scholar
• Cohen C, Shamblaw D, Ruane P, Single-tablet, fixed-dose regimen of elvitegravir/emtricitabine/tenofovir disoproxil fumarate/GS-9350 achieves a high rate of virologic suppression and GS-9350 is an effective booster. 16th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA; 2010
   Google Scholar